Omada Health (NASDAQ:OMDA) Price Target Cut to $22.00 by Analysts at Canaccord Genuity Group

Omada Health (NASDAQ:OMDA) had its target price lowered by analysts at Canaccord Genuity Group from $28.00 to $22.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 56.92% from the company’s current price.

Several other research analysts also recently weighed in on the company. Evercore boosted their price target on Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 7th. The Goldman Sachs Group reiterated a “buy” rating and issued a $26.00 target price on shares of Omada Health in a research note on Friday, January 16th. Weiss Ratings restated a “sell (d)” rating on shares of Omada Health in a report on Thursday, January 22nd. Barclays lowered their target price on Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company began coverage on Omada Health in a report on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.90.

Omada Health Stock Performance

OMDA traded up $0.42 on Friday, hitting $14.02. 4,178,368 shares of the company were exchanged, compared to its average volume of 1,287,286. The business’s fifty day moving average is $14.07 and its 200 day moving average is $18.73. Omada Health has a fifty-two week low of $10.28 and a fifty-two week high of $28.40. The firm has a market capitalization of $811.90 million and a P/E ratio of -56.08.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million for the quarter.

Insider Transactions at Omada Health

In other Omada Health news, CEO Sean P. Duffy sold 40,796 shares of Omada Health stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $15.95, for a total value of $650,696.20. Following the completion of the transaction, the chief executive officer directly owned 126,644 shares in the company, valued at $2,019,971.80. The trade was a 24.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Wei-Li Shao sold 5,618 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $16.13, for a total value of $90,618.34. Following the sale, the president owned 69,079 shares in the company, valued at $1,114,244.27. The trade was a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 276,893 shares of company stock valued at $4,336,787.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Omada Health in the 4th quarter valued at approximately $297,000. Utah Retirement Systems bought a new position in shares of Omada Health in the fourth quarter worth $1,237,000. VARCOV Co. acquired a new position in shares of Omada Health during the fourth quarter valued at $504,000. Voloridge Investment Management LLC bought a new stake in shares of Omada Health during the fourth quarter valued at about $2,590,000. Finally, Tudor Investment Corp ET AL lifted its holdings in Omada Health by 373.7% in the fourth quarter. Tudor Investment Corp ET AL now owns 211,416 shares of the company’s stock worth $3,336,000 after purchasing an additional 166,783 shares during the period.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 beat and improving profitability — Omada reported $0.08 EPS vs. ($0.04) consensus and $75.85M revenue; Q4 revenue +58% YoY, member growth +55%, positive Q4 net income and full-year positive adjusted EBITDA. Omada Health Reports Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: New product launches and growth target — Omada launched GLP-1 Flex Care and new GLP-1/cholesterol programs and outlined a 22% revenue growth target for 2026, which supports recurring revenue expansion and employer uptake. Omada outlines 22% revenue growth target & launches GLP-1 programs
• Positive Sentiment: Wall Street support remains — Goldman Sachs maintained a Buy rating with a $26 price target, signaling continued analyst conviction despite mixed PT moves elsewhere. Goldman maintains Buy on Omada
• Neutral Sentiment: FY2026 revenue guidance roughly in line with consensus — Company issued revenue guidance of $312M–$322M vs. consensus ~$312.2M; guidance is broadly in line but execution will matter. FY2026 guidance (press release)
• Neutral Sentiment: Morgan Stanley trimmed its PT modestly from $32 to $30 but kept an Overweight rating — still implies sizable upside, so this is less negative than a rating downgrade. Morgan Stanley price-target note
• Negative Sentiment: BMO cut its price target sharply from $27 to $18 (Outperform) — a notable reduction in upside expectations that may cap near-term analyst-driven gains. BMO lowers Omada price target
• Negative Sentiment: Barclays lowered its PT to $17 — another downgrade to analysts’ absolute target levels that increases headline risk despite operational momentum. Barclays lowers Omada target

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.